- VitalHub has acquired BookWise Solutions, a company that offers scheduling software for healthcare and corporate organizations
- Through the acquisition, the company expects to expand its suite of patient flow products and add 150 customers in Australia and the United Kingdom
- BookWise products enable users to manage their resources, including specialist oncology scheduling, special day unit scheduling, outpatient scheduling, renal scheduling and doctor study leave management
- Shares of VitalHub are up 3.21 per cent to C$4.83 as of 12:39 pm ET
VitalHub (TSX:VHI) is set to acquire BookWise Solutions, a company that offers scheduling software for healthcare and corporate organizations.
In a news release, the company stated it expects to expand its suite of patient flow products and add more than 150 customers across Australia and the United Kingdom.
“In particular, there are strong synergies with our Intouch with Health platform. BookWise has developed an excellent solution that encompasses the healthcare domain in a unique fashion that we believe can be sold in all of our geographies,” Dan Matlow, CEO of VitalHub, said in a statement. “We welcome the BookWise team to team VitalHub!”
Under BookWise’s suite of products, users can manage their resources including specialist oncology scheduling, special day unit scheduling, outpatient scheduling, renal scheduling, doctor study leave management and real-time room and facilities booking.
Based out of Burton-on-Trent, England, and founded in 2010, BookWise Solutions specializes in scheduling software for healthcare and corporate organizations.
VitalHub provides technology to health and human services providers including hospitals, regional health authorities, mental health, long-term care, home health and community and social services.
Shares of VitalHub are up 3.21 per cent to C$4.83 as of 12:39 pm ET.
Join the discussion: Find out what everybody’s saying about this stock on the VitalHub Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
